RespireRx Pharmaceuticals — Investor Presentation (May 2021)
18 slides from RespireRx Pharmaceuticals's investor presentation, May 6, 2021
Slide 1: RespireRx Summary Presentation May 2021
RespireRx Pharmaceuticals Inc (OEQB- RSP SUMMARY PRESENTATION May 2021
Slide 2: Cautionary Notes: Forward Looking Statements
CAUTIONARY NOTES WN RespireRx espires Inc FORWARD LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Company intends that such forward-looking
Slide 3: Cautionary Notes (cont'd): Not a Securities Offering
CAUTIONARY NOTES (cont’d) WN RespireRx espires Inc NOT A SECURITIES OFFERING This presentation does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by RespireRx Pharmaceuticals Inc. (the “Company’) or any other t
Slide 4: Cautionary Notes (cont'd): Summary Risk Factors
CAUTIONARY NOTES (cont'd) WN RespireRx espires Inc SUMMARY RISK FACTORS This presentation speaks to RespireRx’s plans, including financing plans, use of the anticipated proceeds from those financings, clinical development plans and things the Company is working on now, but where results will occur i
Slide 5: Summary of Proposed Terms of Tier 2 Regulation A Offering
Summary of Proposed Terms of Tier 2 Regulation A Offering 5 : Resp ireRx pespirer Inc OTC QB:RSPI Key Elements: O Estimated submission to the SEC in [2™ Quarter] 2021 O Effective Date TBD. Based on SEC review QO Anticipated to be a continuous offering C Estimated size ~$5-7 million Q Pricing at disc
Slide 6: RespireRx - Underlying Science
RespireRx — Underlying Science QRespireRx Pharmaceuticals Inc Neurotransmission * Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. * RespireRx is developing breakthrough cues to PATEL BUTS
Slide 7: RespireRx - Organizational Structure
RespireRx - Organizational Structure AQ RespireRx _J. Cook PhD — Research Fellow - Chemistry
Slide 8: Key Intended Uses of Funding
Key Intended Uses of Funding A RespireRx See ce Inc Assuming completion of financing and subject to adequate availability of funds Q Complete corporate restructuring plans i Progress clinical development programs Q Develop a proprietary Dronabinol drug product formulation and prepare for Phase 3 Q E
Slide 9: Corporate Re-Organization Plans
Corporate Re-Organization Plans dQ RespireRx Pharmaceuticals Inc RespireRx Pharmaceuticals. Inc. (OTCQB:RSPI) *ResolutionRx *EndeavourRx Pharmaceutical Cannabinoids Neuromodulators *We are contemplating the reorganization as there are several advantages to separating these platforms formally into ne
Slide 10: Product Candidate Portfolio Summary
Product Candidate Portfolio Summary GdResp pireRx | ResolutionRx | Pharmaceutical Cannabinoids Dronabinol (A9-THC) Treatment of Obstructive Sleep Apnea (OSA) No approved drugs available for OSA Potential multi-billion dollar market — estimated 30 million US patients Statistically significant endpoin
Slide 11: RespireRx - Pipeline Development Status
RespireRx - Pipeline Development Status NW RespireRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA —— Dronabinol Formulation == EndeavourRx - Neuromodulators AMPAkKines €X717 - ADHD Sp CX1739 - Spinal Cord Injury er CX1942 —-follow-up compound =
Slide 12: Dronabinol Development Timeline
RespireRx ooeuen Inc Adequate Finance Dronabinol Development Timeline Pending Availability of ; : Period Post-Finance 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 20 Formulation Development. —=)> FDA Pre-IND Meeting —= IND Submission and Approval » Clinical PK/PD in OSA =) Clinical "Likeability" Study ==>
Slide 13: Priority Intended Uses of Initial Funding
Priority Intended Uses of Initial Funding RN Resp ireRx Respiey Inc | ResolutionRx | | EndeavourRx | Dronabinol (A9-THC) AMPAkines Complete proprietary formulation work Initiate SCI phase 2A studies PK studies with new formulation Patent filings Patent filings GABAkines = IND meeting with FDA : = Co
Slide 14: Global Market Opportunities
Global Market Opportunities GdResp pireRx | ResolutionRx | Dronabinol (A9-THC) Obstructive Sleep Apnea (OSA): Multi-billion dollar market with no approved drugs available Estimated 30 million US patients and 28 million in UK and Germany combined Improved formulation may offer potential for improved
Slide 15: Intellectual Property
Intellectual Property Resp pireRx | ResolutionRx | Dronabinol (A9-THC) License to issued method-of-use patent in the US, for the use of dronabinol for treating OSA (expires 2025 in U.S.) Pending patents on broad, enabling dosage and modified release formulations with patent life through at least 203
Slide 16: Government Protection from Generic Competition
Government Protection from Generic Competition YResp pireRx Pharmaceuticals Inc | Data exclusivity programs create strong barriers to market entry that are automatically granted | and enforced by the medicines regulatory system, without exceptions or limitations | * Data exclusivity is a government
Slide 17: Corporate Summary
xX S & Corporate Summary ow RespireRx ph od li Inc Highly desirable assets — advancing clinical programs and patent estate Diverse portfolio of novel products across multiple therapeutic categories and indications Broad flexibility in identifying unique investment structures Opportunities for strate
Slide 18: RespireRx Contacts
RespireRx Pharmaceuticals Inc OICQBIRSED (Contacts: Vw Jones, Presigia & CEO Uchestreserccoo BEES) Neti Matgolsy ero) UMmAargOls@reSPILeLxec On QUIRES AUG
RespireRx Pharmaceuticals — Investor Presentation (May 2021) on 6ix